scholarly journals Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study

2018 ◽  
Vol 144 (2) ◽  
pp. 263-272 ◽  
Author(s):  
Marissa C. van Maaren ◽  
Linda de Munck ◽  
Luc J.A. Strobbe ◽  
Gabe S. Sonke ◽  
Pieter J. Westenend ◽  
...  
2018 ◽  
Vol Volume 10 ◽  
pp. 5329-5338 ◽  
Author(s):  
Weikai Xiao ◽  
Shaoquan Zheng ◽  
Anli Yang ◽  
Xingcai Zhang ◽  
Yutian Zou ◽  
...  

2015 ◽  
Vol 35 (2) ◽  
pp. 95-102 ◽  
Author(s):  
Farid Cherbal ◽  
Hadjer Gaceb ◽  
Chiraz Mehemmai ◽  
Insaf Saiah ◽  
Rabah Bakour ◽  
...  

2019 ◽  
Vol 17 (6) ◽  
pp. 676-686 ◽  
Author(s):  
Mei-Chin Hsieh ◽  
Lu Zhang ◽  
Xiao-Cheng Wu ◽  
Mary B. Davidson ◽  
Michelle Loch ◽  
...  

Background: Breast cancer subtype is a key determinant in treatment decision-making, and also effects survival outcome. In this population-based study, in-depth analyses were performed to examine the impact that breast cancer subtype and receipt of guideline-concordant adjuvant systemic therapy (AST) have on survival using a population-based cancer registry’s data. Methods: Women aged ≥20 years with microscopically confirmed stage I–III breast cancer diagnosed in 2011 were identified from the Louisiana Tumor Registry. Breast cancer subtypes were categorized based on hormone receptor (HR) and HER2 status. Guideline-concordant treatment was defined using the NCCN Guidelines for Breast Cancer. Logistic regression was applied to identify factors associated with guideline-concordant AST receipt. Kaplan-Meier survival curves were generated to compare survival among subtypes by AST receipt status, and a semiparametric additive hazard model was used to verify the factors impacting survival outcome. Results: Of 2,214 eligible patients, most (70.8%) were HR+/HER2– followed by HR–/HER2– (14.4%), and 78.6% received guideline-concordant AST. Compared with patients with the HR+/HER2+ subtype, women with other subtypes were more likely to be guideline-concordant after adjusting for sociodemographic and clinical variables. Women with the HR–/HER2+ or HR–/HER2– subtype had a higher risk of any-cause and breast cancer–specific death than those with the HR+/HER2+ subtype. Those who did not receive AST had an additional adjusted hazard of 0.0191 (P=.0001) in overall survival and 0.0126 (P=.0011) in cause-specific survival compared with those who received AST. Conclusions: Most patients received guideline-concordant AST, except for those with the HR+/HER2+ subtype. Patients receiving guideline-adherent adjuvant therapy had better survival outcomes across all breast cancer subtypes.


2015 ◽  
Vol 26 (12) ◽  
pp. 1737-1750 ◽  
Author(s):  
Adana A. M. Llanos ◽  
Sheenu Chandwani ◽  
Elisa V. Bandera ◽  
Kim M. Hirshfield ◽  
Yong Lin ◽  
...  

2018 ◽  
Vol 92 ◽  
pp. S130
Author(s):  
L. De Munck ◽  
M.C. Van Maaren ◽  
L.J.A. Strobbe ◽  
M.L. Smidt ◽  
P.M.P. Poortmans ◽  
...  

2013 ◽  
Vol 130 (3) ◽  
pp. 609-614 ◽  
Author(s):  
M. Puig-Vives ◽  
M.J. Sánchez ◽  
J. Sánchez-Cantalejo ◽  
A. Torrella-Ramos ◽  
C. Martos ◽  
...  

2018 ◽  
Vol 92 ◽  
pp. S49
Author(s):  
E. Heeg ◽  
K. Schreuder ◽  
P.E.R. Spronk ◽  
J.C. Oosterwijk ◽  
S. Siesling ◽  
...  

BMJ ◽  
2014 ◽  
Vol 349 (sep12 1) ◽  
pp. g5410-g5410 ◽  
Author(s):  
N. A. de Glas ◽  
A. J. M. de Craen ◽  
E. Bastiaannet ◽  
E. G. Op 't Land ◽  
M. Kiderlen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document